- Previous Close
37.43 - Open
37.43 - Bid 34.64 x 40000
- Ask 38.55 x 40000
- Day's Range
37.43 - 37.43 - 52 Week Range
31.81 - 55.28 - Volume
100 - Avg. Volume
11 - Market Cap (intraday)
2.783B - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
42.53 - EPS (TTM)
0.88 - Earnings Date Feb 10, 2025
- Forward Dividend & Yield 0.75 (2.01%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese medicine; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air freshener, lens cleaner, cooling gel sheets, and oral hygiene products. It also manufactures and sells pharmaceuticals, cosmetics, and health foods; and manufactures and sells synthetic resin products; markets nutritional supplements and skin care products through mail orders; and sells skincare products, daily necessities, and health foods, as well as manufactures body warmers. In addition, the company engages in transportation, real estate management, and advertising planning and production businesses; manufacture of sanitary and paper products; and asset management. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
www.kobayashi.co.jp3,534
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: KBYPF
View MorePerformance Overview: KBYPF
Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KBYPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KBYPF
View MoreValuation Measures
Market Cap
2.76B
Enterprise Value
2.43B
Trailing P/E
42.63
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.57
Price/Book (mrq)
2.11
Enterprise Value/Revenue
2.24
Enterprise Value/EBITDA
27.51
Financial Highlights
Profitability and Income Statement
Profit Margin
6.03%
Return on Assets (ttm)
5.56%
Return on Equity (ttm)
4.86%
Revenue (ttm)
168.8B
Net Income Avi to Common (ttm)
10.18B
Diluted EPS (ttm)
0.88
Balance Sheet and Cash Flow
Total Cash (mrq)
51.67B
Total Debt/Equity (mrq)
0.47%
Levered Free Cash Flow (ttm)
--